Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Revenue
Forecast
Revenue Estimate
Biomed Lublin Wytwornia Surowic i Szczepionek SA
For the last 8 years the compound annual growth rate for Biomed Lublin Wytwornia Surowic i Szczepionek SA's revenue is 5%. The projected CAGR for the next 1 year is -13%.
Operating Income
Forecast
Operating Income Estimate
Biomed Lublin Wytwornia Surowic i Szczepionek SA
For the last 8 years the compound annual growth rate for Biomed Lublin Wytwornia Surowic i Szczepionek SA's operating income is 15%. The projected CAGR for the next 1 year is -7%.
Net Income
Forecast
Net Income Estimate
Biomed Lublin Wytwornia Surowic i Szczepionek SA
For the last 8 years the compound annual growth rate for Biomed Lublin Wytwornia Surowic i Szczepionek SA's net income is 64%. The projected CAGR for the next 1 year is 8%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is BML's stock price target?
Not Available
BML doesn't have any price targets made by Wall Street professionals.
What is Biomed Lublin Wytwornia Surowic i Szczepionek SA's Revenue forecast?
Projected CAGR
-13%
For the last 8 years the compound annual growth rate for Biomed Lublin Wytwornia Surowic i Szczepionek SA's revenue is 5%. The projected CAGR for the next 1 year is -13%.
What is Biomed Lublin Wytwornia Surowic i Szczepionek SA's Operating Income forecast?
Projected CAGR
-7%
For the last 8 years the compound annual growth rate for Biomed Lublin Wytwornia Surowic i Szczepionek SA's operating income is 15%. The projected CAGR for the next 1 year is -7%.
What is Biomed Lublin Wytwornia Surowic i Szczepionek SA's Net Income forecast?
Projected CAGR
8%
For the last 8 years the compound annual growth rate for Biomed Lublin Wytwornia Surowic i Szczepionek SA's net income is 64%. The projected CAGR for the next 1 year is 8%.
